Biogrowth, Inc.

3065 Atlas Road Suite 117
Richmond, CA 94806

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $225K
First Award Date 02/01/86
Most Recent Award Date 01/01/91

Key Personnel

Last Name Name Awards Contact
Maack Christopher Arthur Maack 1
Spencer E M Spencer 2
Talkington-Verser Carol Ann Talkington-Verser 1
Spratt Dr. Sharon K Spratt 1

5 Awards Won

Phase 2 SBIR

Agency: Department of Agriculture
Topic: 1991
Budget: 01/01/91 - 12/31/91

THE OVERALL GOAL OF THIS PROJECT IS TO DEVELOP A NOVEL, COST-EFFECTIVE CARRIER VEHICLE FOR BOVINE INSULIN-LIKE GROWTH FACTOR (IGF): THE BOVINE IGF CARRIER PROTEIN (BBP3).BBP3 WILL BIND IGF WITH HIGH AFFINITY, PROTECT IT FROM DEGRADATION, AND SLOWLY RELEASE IT IN AN ACTIVE FORM. THEREFORE, BBP3 WILL SIGNIFICANTLY IMPROVE THE BIOACTIVITY OF IGF, P...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/89 - 12/31/89

The ultimate goal of this project is to identify natural variants of the insulin-like-growth-factor carrier protein (IGF-CP) that exhibit enhanced therapeutic potential. Such IGF-CPs may only be synthesized in specific tissues where they interact with IGFs to carry out particular functions. For example, the IGF-CP found in the wound fluid may ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/88 - 01/31/89

A panel of monoclonal antibodies directed against a specific and important growth regulator is being developed. Hybridomas will be isolated, characterized, and cloned. Further characterization of the resultant monoclonal antibodies will be carried out to identify which will be most useful for (a) setting up an ELISA- based system, (b) identify...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/87 - 05/31/88

The long-term objective is to be able to regulate abnormal growth processes that are related to somatomedins. Since somatomedins are the major stimulators of bone formation, they offer real promise in the therapy of post-menopausal osteoporosis. They may also be used to stimulate bone formation around prosthetic joints. The stimulatory proper...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/86 - 07/31/86

The long-term objective is to be able to regulate abnormal growth processes that are related to somatomedins. Since somatomedins are the major stimulators of bone formation, they offer real promise in the therapy of post-menopausal osteoporosis. They may also be used to stimulate bone formation around prosthetic joints. The stimulatory proper...